Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 2.82
(-0.7%)
CNY 2.82
(-0.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.07 Billion CNY | -11.98% |
| 2022 | 12.57 Billion CNY | -24.69% |
| 2021 | 16.7 Billion CNY | -19.73% |
| 2020 | 20.81 Billion CNY | -6.31% |
| 2019 | 22.21 Billion CNY | -5.6% |
| 2018 | 23.53 Billion CNY | 35.94% |
| 2017 | 17.3 Billion CNY | 112.27% |
| 2016 | 8.15 Billion CNY | 49.42% |
| 2015 | 5.45 Billion CNY | 41.64% |
| 2014 | 3.85 Billion CNY | 37.4% |
| 2013 | 2.8 Billion CNY | 27.24% |
| 2012 | 2.2 Billion CNY | 57.38% |
| 2011 | 1.4 Billion CNY | 18.34% |
| 2010 | 1.18 Billion CNY | 46.87% |
| 2009 | 805.77 Million CNY | 33.49% |
| 2008 | 603.64 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 9.9 Billion CNY | -10.56% |
| 2024 Q2 | 10.03 Billion CNY | 1.28% |
| 2024 Q3 | 10.71 Billion CNY | 6.81% |
| 2023 Q3 | 11.73 Billion CNY | -6.08% |
| 2023 FY | 11.07 Billion CNY | -11.98% |
| 2023 Q4 | 11.07 Billion CNY | -5.62% |
| 2023 Q2 | 12.49 Billion CNY | -6.79% |
| 2023 Q1 | 13.39 Billion CNY | 6.52% |
| 2022 Q1 | 17.94 Billion CNY | 7.44% |
| 2022 FY | 12.57 Billion CNY | -24.69% |
| 2022 Q4 | 12.57 Billion CNY | -17.41% |
| 2022 Q3 | 15.23 Billion CNY | -5.8% |
| 2022 Q2 | 16.16 Billion CNY | -9.9% |
| 2021 FY | 16.7 Billion CNY | -19.73% |
| 2021 Q4 | 16.7 Billion CNY | -11.16% |
| 2021 Q2 | 19.43 Billion CNY | -10.87% |
| 2021 Q3 | 18.8 Billion CNY | -3.24% |
| 2021 Q1 | 21.8 Billion CNY | 4.76% |
| 2020 Q3 | 22.77 Billion CNY | 0.1% |
| 2020 FY | 20.81 Billion CNY | -6.31% |
| 2020 Q1 | 23.66 Billion CNY | 6.54% |
| 2020 Q2 | 22.75 Billion CNY | -3.85% |
| 2020 Q4 | 20.81 Billion CNY | -8.64% |
| 2019 Q2 | 25.86 Billion CNY | 2.1% |
| 2019 Q4 | 22.21 Billion CNY | -12.33% |
| 2019 Q3 | 25.33 Billion CNY | -2.04% |
| 2019 FY | 22.21 Billion CNY | -5.6% |
| 2019 Q1 | 25.33 Billion CNY | 7.65% |
| 2018 Q4 | 23.53 Billion CNY | 0.4% |
| 2018 Q3 | 23.43 Billion CNY | 5.45% |
| 2018 Q2 | 22.22 Billion CNY | 16.99% |
| 2018 Q1 | 18.99 Billion CNY | 9.75% |
| 2018 FY | 23.53 Billion CNY | 35.94% |
| 2017 Q1 | 10.24 Billion CNY | 25.68% |
| 2017 Q3 | 14.38 Billion CNY | 22.67% |
| 2017 Q4 | 17.3 Billion CNY | 20.33% |
| 2017 FY | 17.3 Billion CNY | 112.27% |
| 2017 Q2 | 11.72 Billion CNY | 14.41% |
| 2016 Q1 | 6.55 Billion CNY | 20.08% |
| 2016 FY | 8.15 Billion CNY | 49.42% |
| 2016 Q4 | 8.15 Billion CNY | 0.88% |
| 2016 Q3 | 8.08 Billion CNY | 13.43% |
| 2016 Q2 | 7.12 Billion CNY | 8.74% |
| 2015 Q3 | 4.7 Billion CNY | 9.77% |
| 2015 FY | 5.45 Billion CNY | 41.64% |
| 2015 Q2 | 4.28 Billion CNY | 16.74% |
| 2015 Q4 | 5.45 Billion CNY | 15.92% |
| 2015 Q1 | 3.67 Billion CNY | -4.64% |
| 2014 Q3 | 3.36 Billion CNY | 3.42% |
| 2014 Q1 | 3.05 Billion CNY | 9.09% |
| 2014 FY | 3.85 Billion CNY | 37.4% |
| 2014 Q4 | 3.85 Billion CNY | 14.35% |
| 2014 Q2 | 3.25 Billion CNY | 6.5% |
| 2013 Q3 | 2.92 Billion CNY | 10.49% |
| 2013 Q4 | 2.8 Billion CNY | -4.16% |
| 2013 Q2 | 2.64 Billion CNY | 2.34% |
| 2013 FY | 2.8 Billion CNY | 27.24% |
| 2013 Q1 | 2.58 Billion CNY | 17.4% |
| 2012 Q4 | 2.2 Billion CNY | 0.76% |
| 2012 Q3 | 2.18 Billion CNY | 21.22% |
| 2012 Q1 | 1.77 Billion CNY | 26.89% |
| 2012 Q2 | 1.8 Billion CNY | 1.54% |
| 2012 FY | 2.2 Billion CNY | 57.38% |
| 2011 Q3 | 1.41 Billion CNY | 3.27% |
| 2011 Q4 | 1.4 Billion CNY | -0.73% |
| 2011 Q1 | 1.18 Billion CNY | 0.12% |
| 2011 Q2 | 1.36 Billion CNY | 15.3% |
| 2011 FY | 1.4 Billion CNY | 18.34% |
| 2010 Q4 | 1.18 Billion CNY | 0.0% |
| 2010 FY | 1.18 Billion CNY | 46.87% |
| 2009 FY | 805.77 Million CNY | 33.49% |
| 2008 FY | 603.64 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 26.67 Billion CNY | 58.488% |
| Shenzhen Glory Medical Co.,Ltd. | 1.18 Billion CNY | -835.192% |